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Abstract
Bisphenol A (BPA) has attracted considerable public attention as it leaches from plastic used in food containers, is
detectable in human fluids and recent epidemiologic studies link BPA exposure with diseases including cardiovascular
disorders. As heart-toxicity may derive from modified cardiac electrophysiology, we investigated the interaction between
BPA and hNav1.5, the predominant voltage-gated sodium channel subtype expressed in the human heart.
Electrophysiology studies of heterologously-expressed hNav1.5 determined that BPA blocks the channel with a Kd of
25.461.3 mM. By comparing the effects of BPA and the local anesthetic mexiletine on wild type hNav1.5 and the F1760A
mutant, we demonstrate that both compounds share an overlapping binding site. With a key binding determinant thus
identified, an homology model of hNav1.5 was generated based on the recently-reported crystal structure of the bacterial
voltage-gated sodium channel NavAb. Docking predictions position both ligands in a cavity delimited by F1760 and
contiguous with the DIII–IV pore fenestration. Steered molecular dynamics simulations used to assess routes of ligand
ingress indicate that the DIII–IV pore fenestration is a viable access pathway. Therefore BPA block of the human heart
sodium channel involves the local anesthetic receptor and both BPA and mexiletine may enter the closed-state pore via
membrane-located side fenestrations.
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Introduction
Bisphenol A (BPA) is used abundantly in the manufacture of
polycarbonate plastics and epoxy resins. Millions of tons of BPA
are produced annually and it is detectable in the urine and blood
of a large section of the population [1,2,3]. Given the short half-life
(,6 hours) of BPA in the body [4], its frequent detection indicates
that there is pervasive environmental exposure to the compound.
One entry route to the body is ingestion when leached from the
lining of food and beverage containers [5].
Animal studies have linked BPA exposure to changes in brain and
behavior, prostate and breast cancer, miscarriage, birth defects,
diabetes and obesity [6], raising issues concerning BPA safety limits.
Two studies have shown a correlation between urine concentration
of BPA and heart disease in human populations [7,8]. While BPA
has been characterized as an endocrine disruptor, displaying weak
agonistic effects at estrogenic receptors [9,10], the broad spectrumof
suspected BPA-associated diseases, including disorders of the heart,
suggests additional molecular targets may exist.
The electrical excitability of cardiac myocytes is mediated by
ion channels, with the activity of the heart-specific voltage-gated
sodium channel isotype hNav1.5 generating the upstroke of the
action potential. The critical role hNav1.5 plays in cardiac health
is evident from the number of pro-arrhythmogenic channelopa-
thies associated with mutation of the SCN5A gene encoding
hNav1.5, which include long QT syndrome type 3, Brugada
syndrome and sudden infant death syndrome [11]. Conversely,
cardiac dysrhythmias can be treated by modulating hNav1.5
activity using 1A and 1B antiarrhythmics, which are members of
the local anesthetic (LA) class of channel-blocking drugs.
LAs bind to closed-resting states of voltage-gated sodium
channels (Navs) but display greater affinity (.100-fold) for open
or open-inactivated states [12]. As such, their inhibition is most
potent when channels repetitively open and inactivate during
sustained periods of action potential firings that characterize, for
example, cardiac tachy-arrhythmias. The modulated receptor
hypothesis [13] was proposed to account for the state-dependent
difference in LA affinity, whereby the high-affinity binding site is
formed in a ‘use-’ or ‘frequency-dependent’ manner during the
conformational shift from closed-resting to activated or inactivated
states. LAs also block closed-state Nav to produce ‘resting state’ or
‘tonic’ block, albeit with lower affinity [12].
The receptor site for LAs has been localized to the transmem-
brane pore region of Nav, which is formed when the four pseudo-
homologous domains (DI–DIV) of the Nav a-subunit assemble to
form a central ion-conducting pathway. Each domain is comprised
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of six transmembrane helices (S1–S6): S1–S4 form the channel
voltage-sensors, S5 and S6 the pore module and the extracellular
S5–S6 linkers (termed the P-loops) create the selectivity filter. A
number of residues on the DIII and DIV S6 helices contribute to
the LA binding site, with the aromatic residue F1760 forming the
critical binding determinant; both use-dependent and tonic block
is attenuated with mutation of this residue [14,15].
The first crystal structure of a Nav has recently been reported
[16]: NavAb from the bacterium Arcobacter butzleri is a homo-
tetrameric channel. Although its voltage-sensors apparently adopt
an activated-state conformation, the pore domain is tightly
constricted at the cytoplasmic end and therefore adopts a closed-
state conformation. While providing valuable insights into Nav
structural elements such as the selectivity filter, of relevance for
ligand studies is the presence of fenestrations of dimensions
8610 A˚ within the transmembrane region of the pore domain;
they appear to connect the lipid bilayer to the pore lumen.
Payandeh et al. hypothesized that equivalent fenestrations in
eukaryotic Nav channels may provide accessible pathways for
pore-blocking LAs. Indeed, the fenestrations of NavAb are
occupied by the acyl chains of co-crystallized lipid molecules,
thus demonstrating that it is feasible for hydrophobic exogenous
molecules to traverse these fenestrations.
Here we show with whole cell patch-clamp recordings that
currents through hNav1.5 expressed in HEK cells are blocked by
micromolar concentrations of BPA, displaying a tonic and use-
dependent component. Mutagenesis of F1760 to alanine reduced
the BPA-induced tonic and use-dependent block, indicating that
the binding site of BPA overlaps with that of local anesthetics.
Steered molecular dynamics simulations using a hNav1.5 homol-
ogy model indicate that BPA and mexiletine can feasibly access the
closed-state pore via the side fenestrations and thus bind in the
local anesthetic receptor site.
Materials and Methods
Cell Culture and Mutagenesis
The plasmid DNA of hNav1.5 in pTracer was used (gift from
Dirk Isbrandt, Hamburg, Germany) for mutagenesis of F1760A
(Qickchange XL kit, Qiagen GmbH, Hilden) and was performed
according to the instructions of the manufacturer. HEK293 cells
were maintained in Dulbecco’s Modified Eagle’s Medium
(Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine
serum, 100 U/ml penicillin and 100 mg/ml streptomycin, and
incubated at 37uC with 5% CO2. Briefly, HEK293 cells were
plated at low density on 35 mm dishes 24 hours before
transfection. Cells were transfected at 40–70% confluency using
Nanofectin (PAA Laboratories GmbH, Pasching, Austria), ac-
cording to manufacturer’s instructions, with 1 mg of hNav1.5 or
the F1760A mutant of hNav1.5 and 0.5 mg EGFP, and distributed
onto several 35 mm dishes on the following day. Electrophysiology
was performed 18–28 hours following transfections. Only cells
with robust green fluorescence were included in the analysis.
Electrophysiology
Whole-cell patch-clamp experiments were performed at room
temperature using an Axopatch 200A operated by Clampex 9.2
software (Axon Instruments, Molecular Devices, USA) and 1–
2 MV glass electrodes (WPI Inc, USA). The pipette solution
contained (in mM): 140 CsF, 10 NaCl, 1 EGTA, and 10 HEPES;
302 mosmol (pH 7.4, adjusted with CsOH) and the extracellular
bath contained (in mM): 140 NaCl, 3 KCl, 10 glucose,
10 HEPES, 1 MgCl2, 1 CaCl2; 310 mosmol (pH 7.4, adjusted
with NaOH). All reagents were purchased from Sigma Chemical
Company (Deisenhofen, Germany) unless otherwise noted. The
tip of a constantly running gravity-driven perfusion system was
positioned close to the recorded cell and drugs were applied by
switching to bath solution containing the indicated concentration.
BPA was dissolved in ethanol at a stock concentration of 100 mM
and diluted, reaching a maximum final ethanol concentration of
0.3%, whereas lidocaine, lamotrigine and mexiletine were directly
added to the bath solution. Capacitive transients were cancelled,
and series resistances (,5 MV) were compensated by 65–95%.
Leak currents were subtracted digitally online using the P/4
procedure following the test pulses except for recordings of use
dependency, where no leak correction was used. Currents were
filtered at 10 kHz and sampled at 100 kHz, except for steady-state
fast inactivation, where a sampling rate of 20 kHz was
used.Recordings were obtained 4 min after establishing the
whole-cell configuration. The drugs or 0.1% ETHO were applied
after pulse 10 at the indicated concentrations during a series of test
pulses to210 mV for 250 ms every 5 s from a holding potential of
2120 mV. The block occurring 15 pulses after BPA or ETOH
application (Ipost/Ipre =
mean Ipeak,pulse16{25
 
mean Ipeak,pulse1{10
  ) was used as
indicator for tonic block. The resulting single dose response data
were fitted with a Hill function using a Levenberg-Marquard
algorithm of Origin’s non linear curve fitter, where start and end
were set to 0 and 1, respectively. Fitting parameters (Kd) are given
as best fit 6 standard error.
Data analyses were performed using Clampfit 9.2 (Axon
Instruments, Molecular Devices, USA), Excel (Microsoft Corpo-
ration, USA), Origin 7 (OriginLab Corporation, USA), and
Statistica (StatSoft (Europe), Germany). The statistical signifi-
cances of differences between mean(Ipeak,pulse1–10) and mean(-
Ipeak,pulse16–25) were assessed using a paired one-sided Student’s t-
test and was set at p,0.05. For values of the dose-response
curves of WT and the F1760A mutant of hNav1.5 and
comparison of their use-dependent block, ANOVA with posthoc
Fischer LSD analysis was used. All data are presented as mean 6
SEM, unless noted otherwise.
Current-voltage (I–V) relations were obtained using 250 ms
pulses from a holding potential of 2120 mV to a range of test
potentials (290 to +45 mV) in 10 mV steps with 5 seconds
between pulses. The sodium channel conductance GNa was
calculated using the following equation:
GNa~INa
INa
Vm{Erevð Þ
where INa is the amplitude of the current at the voltage Vm, and
Erev is the reversal potential for sodium, which was determined for
each cell individually. Activation curves were derived by plotting
normalized GNa as a function of test potential and fitted using the
Boltzmann equation:
GNa~
GNa,Max
1ze
Vhalf{Vm
k
,
where GNa,Max is the maximum conductance, Vhalf is the
membrane potential at half-maximal activation, Vm is the
membrane voltage and k is the slope factor.
To examine the voltage-dependences of steady-state fast
inactivation, a series of 500 ms prepulses (2160 to 0 mV) from
a Vhold of 2120 mV, each followed by a brief test pulse to
210 mV, were presented at 5 sec intervals. Normalized current
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amplitude (INa/INa,Max) at each test potential was plotted as a
function of prepulse potential (Vm) and fitted using the following
(Boltzmann) equation: INa
INa,max
(V )~
1
1ze
V{Vhalf
k
, yielding the half
maximal inactivation (Vhalf) and the slope factor (k).
Decay time constants were determined by fitting current
recordings at test pulses to 210 mV for 40 ms from peak with a
single exponential fit.
The dissociation constant for the resting channels, Kr, of the
applied drugs were determined according to [17,18]:
Kr~
drug½ 
1
Brest
{1
,
with [drug] being the drug concentration present and Brest being
the detected block of resting channels.
Dissociation constants for inactivated channels, Ki, were
determined by holding the recorded cells at a potential at which
30–50% of channels are inactivated. This potential was deter-
mined for each cell individually by the above described protocol
for steady-state fast inactivation. Test pulses (250 ms) to 210 mV
were applied every 5 sec and the drug was perfused. Ki was
determined as [17,18]:
Ki = 1{hð Þ
Bmax
Bdrug
{1
 
drug½ 
with h being the fraction of inactivated channels at the chosen
holding potential, Bmax being the maximal possible block by the
drug, which was assumed to be complete and therefore set to 1
and Bdrug is the amount of block at [drug].
With Kr and Ki the shift of Vhalf of steady-state fast inactivation
can be predicted with the following equation [17,18]:
DVhalf~k: ln 1z
drug½ 
Ki
 
= 1z
drug½ 
Kr
  
:
When two drugs, drug1 and drug2, are applied simultaneously
the drug induced shift of Vhalf can be predicted for separate
binding sites via:
DVhalf~k : ln 1z
drug1½ 
Ki1
z
drug2½ 
Ki2
 
= 1z
drug1½ 
Kr1
z
drug2½ 
Kr2
  
and for the same or an overlapping binding site via:
DVhalf~k: ln
1z
drug1½ 
Ki1
z
drug2½ 
Ki2
z
drug1½ 
Ki1
: drug2½ 
Ki2
0
BBB@
1
CCCA=
1z
drug1½ 
Kr1
z
drug2½ 
Kr2
z
drug1½ 
Kr1
: drug2½ 
Kr2
0
BBB@
1
CCCA
0
BBB@
1
CCCA
Use-dependent current decline was examined before and after
drug application using 30 test pulses to 210 mV at frequencies of
1 Hz, 10 Hz (for both the test pulse length was 40 ms), 30 Hz (test
pulse 20 ms) and 50 Hz (test pulse 10 ms) fromaholding potential of
2120 mV. Current responses were normalized to the first recorded
pulse and the available currents at the 30th pulses were compared.
Homology Modeling and Automated Ligand Docking
Studies
The 2.7 A˚ crystal structure of the bacterial sodium channel
NavAb (PDB code 3RVY, [16]) was used as the structural
template for construction of a closed-state hNav1.5 homology
model. Sequences were aligned using ClustalW [19] and 50
models were produced using MODELLER [20]. The internal
scoring function of MODELLER was used to select 10 models,
which were visually inspected and submitted to the VADAR
webserver [21] for assessment of stereochemical soundness. The
lead candidate was energy-minimized for 20 picoseconds (ps) using
NAMD molecular dynamics software (version 2.8) [22]. Energy
minimization and molecular dynamics simulations (detailed below)
were carried out in vacuo and, in order to closely preserve the initial
structure of the channel in the absence of solvent molecules yet still
allow a degree of conformational flexibility, a harmonic constraint
of value 0.75 was applied to the model backbone atoms. The
‘solvate’ function of VMD was used to calculate how water
molecules could be accommodated in the model pore and
therefore assess its volume.
Crystal structures of BPA (reference code CEGYOC02) and
mexiletine (reference code JIZJEH) were downloaded from the
Cambridge Structural Database (www.ccdc.cam.ac.uk). Automat-
ed docking predictions of these ligands with the channel model
were generated using Autodock 4 as previously described [23].
Grid maps with 60660660 points and 0.375 A˚ spacing were
constructed to encompass the pore interior. Dockings were
performed using a Lamarckian genetic algorithm [24] with
population size = 150, mutation rate = 0.02, crossover rate = 0.8.
Docking predictions were screened by interaction energy and
proximity (#4 A˚) of the ligand to the side-chain of F1760. Figures
were produced using PyMOL (DeLano Scientific, San Carlos, CA,
U.S.A.).
Steered Molecular Dynamics (SMD) Simulations
SMD simulations of BPA or mexiletine ingressing the closed-
state hNav1.5 pore were performed using NAMD [22]. Topology
and parameter files were generated for the ligands using the
SwissParam web-server (http://swissparam.ch). VMD software
[25] and the PDBSET program of the CCP4 suite [26] were
used to (a) position the hNav1.5 model with the centroid at the
pore center, (b) position either BPA or mexiletine 35 A˚ from the
pore center along a coordinate axis that ran through either a
pore fenestration or the selectivity filter, (c) rotate each positioned
ligand (by changing Euler angles in 120u steps) to produce 21
starting models per fenestration or filter. This approach of using
many starting orientations enabled the comparison of force
calculations for different access routes as it circumvented the bias
that could result if a single orientation was used for all
simulations (since a ligand may more favourably traverse one
pathway based on that particular orientation).
During simulations ligands were drawn towards the pore center
by constant velocity pulling, whereby the ligand was attached by a
virtual spring to a massless ‘‘dummy atom’’ moving at 4 A˚/ps
along a coordinate axis. The force (F) exerted on the ligand was:
F~K(x0zvt{x)
where K=139 picoNewton/A˚ is the spring constant,
v = 0.004 A˚/time-step is the pulling velocity and x and x0 are
the positions of the ligand’s center-of-mass and the end of the
spring, respectively. 20 pS simulations using the CHARMM22
protein force field were carried out at a temperature of 310 K
Bishpenol A Blocks Sodium Channel hNav1.5
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with a 1 femtosecond time-step; electrostatic and van der Waals
interactions were truncated at 12 A˚. VMD was used for
simulation analysis and extraction of the force exerted on the
ligand center-of-mass in the direction of spring movement. The
average values were plotted for the force for each set of
fenestration or filter simulations.
Results
BPA Blocks hNav1.5 Currents
To investigate the effects of BPA on cardiac sodium channel
function, we transiently expressed hNav1.5 in HEK cells and
performed whole-cell patch clamp experiments (Fig. 1). Tonic
block of hNav1.5 by BPA was assessed with depolarizing test
pulses applied at a frequency of 0.2 Hz, which did not induce use-
dependent current decline. Application of micromolar concentra-
tions of BPA induced a dose-dependent tonic block with a Kd of
74.067.6 mM (Hill fit, Fig. 1, green symbols, Vhold=2120 mV,
n=5211). For cells held at more depolarized potentials closer to
the physiological cardiac resting membrane potential
(Vhold=290 mV), this block was more pronounced (Fig. 1, blue
symbols, Kd=25.461.3 mM, n= 5210).
At Vhold=290 mV more hNav1.5 channels are in the
inactivated state than at Vhold=2120 mV. Therefore the
predominant block of BPA at this holding potential may result
from a higher binding affinity of the compound to the inactivated
state, which is the case for LAs, where dissociation constants for
inactivated channels is much lower than for resting channels
(Ki,,Kr). Indeed BPA did enhance use-dependent current
decline at all frequencies tested (1 to 100 Hz, Fig. 1B), without
affecting activation or the time constant of current decay (Vhalf of
activation: 232.062.5 mV (pre) and 232.963.7 mV (post
100mM BPA), t of single exponential fit of current decay:
1.160.08 ms (pre), 1.1360.1 ms (post), test pulse to 210 mV,
n=4, 7).
BPA Shifts Steady-state Fast Inactivation of hNav1.5 to
More Hyperpolarized Potentials, Similar to LAs
100 mM BPA induces a left shift of the voltage-dependence of
steady-state fast inactivation by 15.8 mV, suggesting that it
stabilizes the fast inactivated state (Fig. 1C). LAs induce a shift
of steady-state fast inactivation to more hyperpolarized potentials
and prefer to bind to the inactivated state of the sodium channels
(e.g. [13,27]), comparable to the BPA effect. We therefore
compared the effect of BPA on steady-state fast inactivation with
those of the LAs mexiletine, lidocaine and lamotrigine. As BPA
was dissolved in ethanol, 0.1% ETOH was tested as vehicle,
which induces a small hyperpolarizing shift in Vhalf of steady-state
fast inactivation itself, but this shift is smaller than those found for
BPA or the tested LAs. For all LAs, a higher concentration than
for BPA is needed to attain comparable effects on steady-state fast
inactivation (Fig. 2). For example, 150 mM mexiletine induced a
12.761.2 mV (n= 11) hyperpolarizing shift (Fig. 2C), whereas
only 100 mM BPA is sufficient for a 15.861.1 mV (n= 9) shift in
Figure 1. BPA is a blocker of human heart sodium channels
(hNav1.5). A: Dose response curve of tonic block of hNav1.5 by BPA is
shown as the relative decrease of sodium current response to a square
voltage step to 210 mV (see inset) at various concentrations of BPA
from a Vhold of2120 mV (green circles) or290 mV (blue circles). A dose
response function (solid lines, Hill function, Kd=74.067.6 mM and
25.461.3 mM, for 2120 and 290 mV, respectively) was employed and
its 95% confidence intervals (dotted lines) were determined. n = 6215
per point, * indicates significance in a paired one sided t-test. Value at
0 mM corresponds to a vehicle control with application of 0.1% ETOH.
Inset: Representative current traces recorded from a HEK293t cell
expressing hNav1.5 before and during application of 30 mM BPA.
Vhold=2120 mV. B: Use-dependent block of currents through hNav1.5
expressed in HEK cells (squares) was enhanced by local anesthetics,
such as mexiletine (30 mM, filled triangles, 150 mM, open triangles,
p,0.001 for all frequencies). A similar enhancement was observed with
BPA and is more pronounced at higher frequencies (30mM, filled circles).
Test pulse potential was 210 mV, Vhold=2120 mV, and test pulse
length varied from 10 to 40 ms, depending on the frequency. C: Steady-
state fast inactivation of hNav1.5 before and after application of 100 mM
BPA (n= 9). Cells were held at 2120 mV and fast inactivation was
induced by a 500 ms prepulse to the indicated potentials (see inset).
Available channels were assessed by a step depolarization to 220 mV
and resulting curves were fitted with a Boltzmann function
(Vhalf=289.361.5 mV, k= 5.660.3 pre; and Vhalf =2105.162.1 mV,
k=6.560.2 post application of 100 mM BPA).
doi:10.1371/journal.pone.0041667.g001
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the same direction (see Fig. 2E for comparison). BPA and LAs
share two prominent characteristics: both stabilize the inactivated
state and induce a use-dependent block when applied to hNav1.5-
expressing HEK cells (Fig. 2A). These two similarities suggest that
both substances might share a common binding site in hNav1.5. If
that is the case, then co-application of mexiletine and BPA should
result in a predictable shift of Vhalf of steady-state fast inactivation
when the corresponding Krs and Kis are known (see Methods
[17,18]). With our experimental data we determined Kr and Ki
for BPA (30mM) as: Kr=58.668 mM . Ki=8.262.4 mM, and
for mexiletine (150mM): Kr=606.26127.5 mM ..
Ki=6.661.9 mM. 100 mM as well as 30 mM BPA are sufficient
to induce a hyperpolarizing shift of steady-state fast inactivation
(Fig. 2E) and the low concentration of 30 mM BPA displayed a
prominent tonic block (see Fig. 1A). The shift of Vhalf induced by
30 mM BPA is clearly larger than that induced by 0.1% ethanol
itself (Fig. 2E) and was therefore chosen as concentration for the
following experiments. This concentration corresponds to approx-
imately half the Kd for tonic block (74.067.6 mM, Fig. 1A).
Correspondingly, we chose 150 mM mexiletine, as this is a
concentration that displays both, use-dependent and a small tonic
block (Fig. 1B and 3C), ensuring that this concentration is high
enough to have the drug bound with its binding site.
The broken lines in Fig. 2E indicate the predicted shift in Vhalf
following application of 30 mM BPA, 150 mM mexiletine and a
combination of both for the two cases where a separate versus
single or overlapping binding site exists. As shown in Fig. 2E, our
experimental data predict that BPA and mexiletine share at least
parts of the same binding site.
BPA Binding Site Overlaps with that of Mexiletine
The F1760A mutation of hNav1.5 lies within the known LA
receptor site in the S6 segment of domain IV [12]. Activation of
F1760A-mutated Nav1.5 was not altered compared to WT, but
steady-state fast inactivation was shifted to more depolarized
potentials by 10.5 mV (Fig. 3, Vhalf/k: WT: 290.460.8 mV/
5.160.1 mV, n= 51; F1760A: 279.960.6 mV/5.860.1 mV,
n= 61), as reported previously [12]. F1760A displayed a reduced
tonic and use-dependent block compared to WT hNav1.5 when
150 mM mexiletine was applied, indicating interference with the
binding site of mexiletine on hNav1.5 (Fig. 3C, D, squares and
triangles).
Tonic block of BPA was reduced by the F1760A mutation in
comparison with WT hNav1.5 (Fig. 3C), demonstrating the
importance of this residue for BPA binding. Similarly, the use-
dependent block of 30 mM BPA was robustly reduced at almost all
frequencies tested, strongly suggesting that mexiletine and BPA at
least partly share a common binding site (Fig. 3D).
Figure 2. Effects of local anesthetics on steady-state fast inactivation. Steady-state fast inactivation of hNav1.5 before and after application
of 300 mM lidocaine (A, n = 9), 300 mM lamotrigine (B, n = 4), 150 mM mexiletine (C, n = 10), and co-application of 150 mM mexiletine and 30 mM BPA
(D, n = 4). For protocol see inset in Figure 1C. E: Shift of the midpoints of steady-state fast inactivation of hNav1.5 induced by (from left to right): 0.1%
ETOH, 10 mM, 30 mM and 100 mM BPA, 300 mM lidocaine, 300 mM lamotrigine, 150 mM mexiletine and co-application of 30 mM BPA with 150 mM
mexiletine. Broken lines indicate predictions using the equations from Kuo et al. [18] for a shift of the midpoints of steady-state fast inactivation
following application of a combination of 30 mM BPA and 150 mM mexiletine for the two cases that both drugs bind to separate or the same/
overlapping binding site. Our results indicate that BPA and mexiletine share at least parts of the same binding site.
doi:10.1371/journal.pone.0041667.g002
Bishpenol A Blocks Sodium Channel hNav1.5
PLoS ONE | www.plosone.org 5 July 2012 | Volume 7 | Issue 7 | e41667
Homology Model of hNav1.5 and Docking Predictions for
BPA and Mexiletine
Most Nav closed-state models reported in the literature (e.g.
[28]) were developed using the KcsA potassium channel crystal
structure [29] to produce homology models. However, the recently
determined crystal structure of the bacterial sodium channel
NavAB [16] provides a more suitable template. One consequence
of using this alternative template is that the resulting Nav pore
region has considerably greater internal volume in comparison
with our previous closed-state model based on KcsA [28]: 95
versus 45 water molecules could be accommodated in the pore.
The pore fenestrations in particular contribute to the greater
spaciousness.
We undertook docking predictions to identify a potential
binding site for BPA. These studies suggested that this compound
is capable of binding in a cavity adjacent to the channel selectivity
filter (Fig. 4B). BPA makes contact with residues on the P-loops of
DIII (T1417) and DIV (T1708, S1710) and the DIV S6 (I1756,
I1757, S1759, V1763). However, the most extensive interaction
occurs with F1760 of DIV S6, the side chain of which projects into
the pore lumen. Both phenol rings of BPA contact F1760 and
consequently the compound effectively straddles this side chain. In
contrast, the Y1767 side chain located closer to the cytoplasmic
entrance of the pore is distal from BPA. Y1767 plays an important
role in use-dependent inhibition of LAs but has no significant
impact on tonic block when mutated [30].
The most energetically-favorable docking prediction of mex-
iletine in the vicinity of F1760 positioned this compound in the
same binding pocket as BPA (Fig. 4C). Mexiletine’s amine group is
not in contact with the F1760 ring but instead comes into close
proximity to the selectivity filter. The hydroxyl group of the S1759
residue on DIV S6 is ,4 A˚ away from the LA molecule and has
Figure 3. BPA and mexiletine share an overlapping binding site. A: Representative current traces of the mutant channel F1760A evoked by
stepping the membrane to the indicated potentials. B: Activation and steady-state fast inactivation of WT hNav1.5 (filled squares, n = 10 and 44,
respectively) and the mutant F1760A (open squares, n = 14 and 61, respectively). C: Tonic block of WT hNav1.5 (filled symbols) and the mutant
F1760A (open symbols) by BPA (circles) and mexiletine (triangles) at a holding potential of 2120 mV, tested every 5 s, n = 3215 (for protocol see
Fig. 1A). Straight lines represent results of a Hill fit, with the following Kds: hNav1.5 BPA: 74.067.6 mM; F1760A BPA: 104.166.7 mM; hNav1.5
mexiletine: 595.9641.8 mM; F1750A mexiletine: 1142.5694.0 mM. The mutation significantly reduced the blocking effects of mexiletine and BPA on
hNav1.5. The posthoc test revealed a significant difference for all tested concentrations of BPA and for the highest two concentrations of mexiletine.
D: Repetitive pulsing of F1760A expressing HEK cells induces almost no use-dependent current decline (open symbols), which can be enhanced to a
limited extent by mexiletine (150 mM, open triangles) or BPA (30mM, open circles). In this Figure data for WT hNav1.5 are the same as in Fig. 1B and
are included for comparison (filled symbols). Squares represent use dependencies of the channel without drug application. Asterisks indicate
significant differences compared to the untreated channel (WT, F1760A) for each frequency, respectively.
doi:10.1371/journal.pone.0041667.g003
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Figure 4. Modeling and ligand docking. A: Sequence alignment of the pore regions of NavAb and hNav1.5. Helical regions in the NavAb
structure are indicated by the cartoons above the sequence. Residues shaded in black by sequence show high sequence homology, those in grey
display moderate homology. B–C: Molecular model for the hNav1.5 structure. The protein structure is shown in ribbon mode and the ligands [(B) BPA
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potential for hydrogen bond formation. The aromatic ring of
mexiletine makes a hydrophobic contact with I1756 (hidden
behind the ligand in Fig. 4C), a residue that was found to
negatively affect tonic block – but not use-dependent block – when
mutated [12]. As with BPA, mexiletine does not contact the Y1767
side chain, as they are located .12 A˚ apart.
SMD Simulations of Ligand Ingression
Both BPA and mexiletine display a prominent tonic block
indicating that the compounds gain access to the closed-state pore.
As the intracellular face of the pore is tightly occluded in the closed
conformation, the ligands must gain access via an alternative
route: either the selectivity filter or the side fenestrations.
Constant-velocity SMD simulations were undertaken to assess
and compare possible routes for BPA and mexiletine ingress. In
these studies the ligand is considered to be attached by a virtual
spring to a point that moves through space at constant velocity. If
the ligand encounters an impediment to movement, the spring
stretches and the resultant force can be calculated. The four pore
fenestrations (Fig. 5A) and the selectivity filter of the hNav1.5
model represent constriction points of different shape and
dimensions and therefore present different energetic barriers to a
mobile ligand, which may have to displace side-chains and
possibly backbone atoms of residues lining the pathway in order to
traverse.
Fig. 5B and C show the calculated forces exerted on BPA or
mexiletine as the ligand progresses from exterior to interior of
the channel pore via different routes. Both BPA and mexiletine
require the application of an extensive force (.3,000 pN) to
permit their transit through the pathway involving the tightly-
constricted selectivity filter (Fig. 5B/C, black traces). In stark
contrast, a force of ,700–900 pN for BPA and of ,450–
1200 pN for mexiletine was sufficient to navigate the fenestra-
tions. The force profiles for each fenestration differ, which
reflects the pseudosymmetry of the Nav1.5 structure. BPA
traverses two of the four fenestrations with apparent ease
and (C) mexiletine] are shown in space-filling mode. The estimated free-energy of binding is 26.12 kcal/mol for BPA and 24.11 kcal/mol for
mexiletine. Selected channel residue side chains are depicted as green sticks and the accessible surface is shown with 70% transparency. Domains I
and II are not displayed to aid visualization.
doi:10.1371/journal.pone.0041667.g004
Figure 5. Side fenestrations offer a new entrance pathway. A: Surface representations of hNav1.5 side fenestrations as viewed from the
membrane. The model is colored by domain with the central white region showing the fenestration located at the interface of each domain pair. B–C:
Force exerted on the center-of-mass of BPA (B) or mexiletine (C) during steered molecular dynamics simulations. Each trace is the averaged force from
21 simulations displayed as mean 6 SEM.
doi:10.1371/journal.pone.0041667.g005
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compared to mexiletine (DI–DII and DII–DIII: ,700 and
,850 pN for BPA; .1200 pN for mexiletine, respectively).
Both compounds encounter a similar resistance when traversing
DIV–DI side opening (,700 pN), and mexiletine needs less
maximal force than BPA for only one entrance path, the side
fenestration between DIII and DIV (BPA: ,950 pN; mexiletine:
,450 pN). The differences derive from dissimilar flexibility and
lateral movement of the compounds through the fenestration
(see video S1, S2, S3, S4).
Discussion
With this study we have identified for the first time a cardiac
target for BPA: the compound blocks currents through hNav1.5 in
a tonic- and use-dependent manner. The modulation profiles of
hNav1.5 by BPA and LAs share striking similarities. Both ligand
types have a higher affinity for the inactivated state (Kr.Ki),
display a shift of steady-state fast inactivation to more hyperpo-
larized potentials and, in addition to a strong tonic component,
both show a strengthening of use-dependent current decline. The
effect on steady-state fast inactivation of co-applied BPA and
mexiletine (Fig. 2) was not additive; the observed shift instead
indicated competitive binding. To test the hypothesis that the
compounds exert their modulation via interaction with a common
receptor site, BPA and mexiletine were tested with the F1760A
mutant. This single substitution greatly attenuated both use-
dependent and tonic block by BPA (Fig. 3), thus marking another
commonality with LAs [12,14,31,32,33] and supporting the
prediction of an overlapping binding site in the pore.
F1760 is a critical binding determinant for LAs and engages
pore-blockers in two distinct interactions depending on the
functional state of Nav. For use-dependent block of the open-
inactivated pore, an aromatic side-chain is required at the F1760
position to satisfy a putative cation-p interaction with the tertiary
amine of a LA [12,14,15]. However, BPA lacks a charge and its
interaction with the open-inactivated pore may therefore share
similarities with LAs that are neutral at physiological pH e.g.
benzocaine, phenytoin or carbamazepine [31,34]. For tonic block,
the physicochemical requisite is hydrophobicity – not aromaticity –
for interaction at the F1760 position [30], which suggests an
alteration in ligand contacts between the open- and closed-state
pore in accordance with the modulated receptor hypothesis [13].
The Kis for mexiletine and BPA are almost the same although
mexiletine displays a larger apparent use-dependent block. This
may be due to the higher solubility of mexiletine in water, which
would allow quicker access to the binding site from the
intracellular side when the channel is opening repetitively. Ki,
on the other hand, was determined after the cells were held on an
inactivating potential for several seconds, rendering time-depen-
dent processes less relevant. 30 mM BPA and 30 mM mexiletine
both induce significant use-dependent block (Fig. 1B), whereas
tonic block with 30 mM mexiletine is almost absent. This also
suggests that BPA accesses the binding site in the closed-state
channel with comparatively greater ease than mexiletine.
The availability of a bacterial sodium channel crystal structure
[16] has enabled us to examine the structural basis of tonic block
using a hNav1.5 homology model. Automated docking predictions
identified a common binding site for both BPA and mexiletine in a
hydrophobic cavity atop the F1760 side chain on S6 of domain IV
(Fig. 4B–C). This pronounced cavity was not evident in a previous
closed-state Nav model based on the KcsA potassium channel
crystal structure [28]. F1760 forms significant van der Waals
contact with both docked ligands and, in agreement with our
electrophysiology data, its mutation to the small side-chain alanine
residue would diminish a key underpinning contact. It is the
hydrophobic section and not the amine group of mexiletine that
contacts F1760, which precludes a cation-p-interaction and is
consistent with the hydrophobic but not aromatic requirement at
this position for tonic block [30]. Therefore this tonic block
receptor is distinct from the use-dependent-block binding site for
which residue Y1767 was shown to be important [30]. Y1767 does
not appear to form part of the BPA binding site. Significant
structural rearrangements would be necessary to reposition a LA
to form a cation-p interaction with F1760 and simultaneously
contact Y1767 (e.g. a change in the F1760 side-chain rotamer,
[12]). In the structural model Y1767 is closer to the cytoplasmic
pore opening and may represent the first major binding
determinant for substances entering the pore from the intracellular
side (use-dependent block). F1760 on the other hand is closer to
the side fenestrations, offering a possible binding site for molecules
potentially entering via this pathway (tonic block).
BPA is a potent tonic blocker (Kr=58.668 mM) and its affinity
for the closed-state pore may derive from its considerable
hydrophobicity (logP 4.04; Table S1). The docking predictions
identify I1756 as a key hydrophobic contributor to the tonic-block
receptor (Fig. 4B–C, located behind the ligands). Mutation of
I1756 to alanine produces a modified tonic block, not necessarily
due to altered binding, but it seems to ease access to the pore for
extracellularly-applied LAs [12,35,36]. Permanently-charged de-
rivatives of lidocaine are unable to partition completely in the
membrane but can still access the closed-state pore of the I1756A
mutant. Studies with m-conotoxin rule out the selectivity filter as
the route for this novel entry pathway [36]. I1756 is located in the
model in the vicinity of the predicted interface between the lipid
bilayer, extracellular solution and the DIII–DIV side fenestration.
It is possible that substitution to the small side chain alanine
enlarges the DIII–DIV side fenestration, such that a charged LA
molecule which is semi-partitioned in the lipid bilayer and
orientated with the tertiary amine contacting negatively-charged
lipid head group(s) may diffuse laterally into the pore, passing
I1756A.
We employed the hNav1.5 model to qualitative assess potential
routes for BPA or mexiletine ingress using SMD simulations. The
force exerted on the mobile ligand during the simulations was used
as a descriptor of how well the ligand would fit through the access
pathway (Fig. 5B–C). The highly-constricted selectivity filter
comprised the path of greatest resistance for both ligands while
the pore fenestrations were comparably more accessible. The four
fenestrations hindered the crossing of BPA to a similar extent
(peaks of ,700–900 pN in the force profiles; Fig. 5B) but in the
case of the more flexible mexiletine the fenestration at the DIII–
DIV interface proved most accessible (peak of ,425 pN), whereas
DI–DII and DII–III showed a higher resistance to mexiletine than
to BPA entry. A ligand ingressing the pore via the DIII–DIV
fenestration would directly contact F1760 and therefore be in
favorable position to occupy the tonic-block receptor. The
compatibility of the DIII–DIV fenestration with closed-state
ligand ingress when compared with the selectivity filter correlates
with results from an analogous study by Bruhova et al. [37].
However, this latter study used the KcsA potassium channel
structure as template and consequently the pore fenestrations of
the Nav homology model were significantly smaller.
BPA exposure has recently been linked to heart disease [7,8],
raising the question of a cardiac target. The highest reported blood
level of BPA is 290 nM [38], which is still lower than 1 mM, the
lowest concentration to have a significant effect on hNav1.5 in our
study (Fig. 1A). The lowest concentration tested at which hNav1.5
currents were not affected was 100 nM (no effect level, NOEL).
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The mean human blood levels are reported to be ,10 nM [39],
just within the tolerable range, according to safety calculations
based on these results. There might be a very slight risk that BPA
may have adverse effects on cardiac function, especially if patients
are preconditioned (e.g. treated with class 1 antiarrhythics). Still,
arrhythmias induced by BPA via its effects on Nav1.5 alone do not
seem very likely. Our recordings were performed in a heterologous
expression system at room temperature, and many factors may
influence potential cardiac BPA effects in physiological conditions,
such as additional binding proteins and body temperature. We
have determined a short term effect of BPA, and potential long
term effects of BPA exposure to cardiac function remain to be
investigated.
BPA was shown to affect voltage-gated sodium currents in
dissociated dorsal root ganglion neurons [40]. However, these
studies did not investigate BPA action in a defined heterologous
expression system or identify a specific binding site.
In this study, we have identified the first cardiac-specific target
for BPA and further localized its binding site to the LA receptor in
the hNav1.5 pore. Modeling and computational methods provide
a basis for understanding BPA-binding interactions in the closed-
state channel and assess routes for entry into the pore lumen. Our
data may contribute to the on-going debate on BPA safety limits at
a time of heightened public concern about BPA exposure.
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